This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2006 Jul 24;166(14):1440-1.

doi: 10.1001/archinte.166.14.1440.

Phase 1 clinical trials: not just for safety anymore?

Janardan Khandekar, Melin Khandekar

PMID: 16864752
DOI: 10.1001/archinte.166.14.1440

Comparative Study

Phase 1 clinical trials: not just for safety anymore?

Janardan Khandekar et al. Arch Intern Med. 2006.

. 2006 Jul 24;166(14):1440-1.

doi: 10.1001/archinte.166.14.1440.

Authors

Janardan Khandekar, Melin Khandekar

PMID: 16864752
DOI: 10.1001/archinte.166.14.1440

No abstract available

PubMed Disclaimer

Comment on

"Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Markman M. Markman M. Arch Intern Med. 2006 Jul 24;166(14):1446-8. doi: 10.1001/archinte.166.14.1446. Arch Intern Med. 2006. PMID: 16864753 Review. No abstract available.

Similar articles

[Methodological approaches of clinical studies with targeted therapies].
Penel N, Saleron J, Lansiaux A, Clisant S, Adenis A, Fournier C, Duhamel A, Bonneterre J. Penel N, et al. Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575. Bull Cancer. 2008. PMID: 18304903 Review. French.
Phase 1 clinical trials nursing: determining safety and side effects on the road approval.
Lindberg D. Lindberg D. ONS Connect. 2012 Jul;27(7):10-4. ONS Connect. 2012. PMID: 22855983 No abstract available.
Three-dose-cohort designs in cancer phase I trials.
Huang B, Chappell R. Huang B, et al. Stat Med. 2008 May 30;27(12):2070-93. doi: 10.1002/sim.3054. Stat Med. 2008. PMID: 17764082
Phase 1 clinical trials in oncology.
Miller MJ. Miller MJ. N Engl J Med. 2005 Jun 9;352(23):2451-3; author reply 2451-3. N Engl J Med. 2005. PMID: 15948270 No abstract available.
Dose selection in phase I studies: why we should always go for the top.
Sleijfer S, Wiemer E. Sleijfer S, et al. J Clin Oncol. 2008 Apr 1;26(10):1576-8. doi: 10.1200/JCO.2007.15.5192. Epub 2008 Mar 10. J Clin Oncol. 2008. PMID: 18332465 Review. No abstract available.

See all similar articles

Cited by

Trends of Phase I Clinical Trials in the Latest Ten Years across Five European Countries.
Di Tonno D, Perlin C, Loiacono AC, Giordano L, Martena L, Lagravinese S, Rossi F, Marsigliante S, Maffia M, Falco A, Piscitelli P, Miani A, Esposito S, Distante A, Argentiero A. Di Tonno D, et al. Int J Environ Res Public Health. 2022 Oct 28;19(21):14023. doi: 10.3390/ijerph192114023. Int J Environ Res Public Health. 2022. PMID: 36360902 Free PMC article.
Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements.
de Melo-Martín I, Sondhi D, Crystal RG. de Melo-Martín I, et al. Mol Ther. 2012 Jun;20(6):1095-102. doi: 10.1038/mt.2012.90. Mol Ther. 2012. PMID: 22652997 Free PMC article. No abstract available.
Evaluation of novel drugs using fMRI in early-phase clinical trials: safety monitoring.
George E, Becerra L, Upadhyay J, Schmidt U, Borsook D. George E, et al. Drug Discov Today. 2010 Aug;15(15-16):684-9. doi: 10.1016/j.drudis.2010.05.008. Epub 2010 May 27. Drug Discov Today. 2010. PMID: 20553959 Free PMC article. Review.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems